1200 participants
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-22
- Start Date:
- 2024-04-14
- Completion:
- 2027-07-11
Conditions
- Breast Neoplasms
Interventions
- DRUG
- BIOLOGICAL
No Results Yet